Skip to main navigation Skip to search Skip to main content

Corrigendum to ‘Inhibition of HDACs-EphA2 signaling axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer’ [EBioMedicine 31 (2018) 276–286](S2352396418301580)(10.1016/j.ebiom.2018.05.003)

  • Tao Zhang*
  • , Jingjie Li
  • , Xiaojun Ma
  • , Yang Yang
  • , Wei Sun
  • , Wangrui Jin
  • , Lei Wang
  • , Yuan He
  • , Feifei Yang
  • , Zhengfang Yi
  • , Yingqi Hua
  • , Mingyao Liu
  • , Yihua Chen
  • , Zhengdong Cai
  • *Corresponding author for this work
  • Shanghai Jiao Tong University
  • Shanghai Bone Tumor Institution
  • East China Normal University
  • University of Jinan
  • Texas A&M University

Research output: Contribution to journalComment/debate

Abstract

The published version of this article contained an error in Fig. 2c and f, the corrected Fig. 2 is included below, the authors declare that the corrections do not change the results or conclusions of this paper and apologize for any inconvenience this may have caused.

Original languageEnglish
Article number102629
JournaleBioMedicine
Volume52
DOIs
StatePublished - Feb 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Corrigendum to ‘Inhibition of HDACs-EphA2 signaling axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer’ [EBioMedicine 31 (2018) 276–286](S2352396418301580)(10.1016/j.ebiom.2018.05.003)'. Together they form a unique fingerprint.

Cite this